Create accountLogin

Recent searches

No recent searches

Search options

Not available on lingo.lol.
lingo.lol is one of the many independent Mastodon servers you can use to participate in the fediverse.
A place for linguists, philologists, and other lovers of languages.

Administered by:

Server stats:

70
active users

lingo.lol: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#waning

0 posts0 participants0 posts today
Public
datum (n=1)

@www.cidrap.umn.edu "Immunity was 81%" is such a BS phrasing without giving a time though CIDRAP! It's right in your title that waning is key!!

The article itself is SO much more accurate!

"Effectiveness rapidly declined after the previous infection, dropping from 81.3% at 3 to 6 months to 59.8% in the next 3 months and 27.5% in the 3 months after that. Protection was negligible after 1 year. Efficacy was 59.5% in the first year, plummeting to 4.8% thereafter.

Overall effectiveness against symptomatic reinfection was 45.4%, declining rapidly thereafter"

Many people only read headlines! 😦 🙃 😦

#CovidConscious#CovidIsNotOver#SARSCoV2
Public
Mike In The Spring Garden

#Happy #Wednesday.
An almost #perfect #autumn day.

The diminishing #crescent of the #waning #moon should be visible tonight as long as the clouds stay near to the horizon.

Nectar rich autumn #flowers are a real treat for the #bees who are scurrying about, collecting every last whisp of goodness from the star like flowers before the #seasons turn and things transform from green to brown.

The season of glorious decay is just a heartbeat away.

Have yourselves a great day out there.

Public
Ian M. Mackay, PhD (he/him)

"#Omicron #reinfection is high, but with lower severity than first infections; reinfection risk is likely driven as much by viral evolution as #waning #immunity"
#COVID19
-don't forget *viral change* (so that it escapes past immunity) is a key driving factor, not just "waning immunity".
medrxiv.org/content/10.1101/20

medRxivRisk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general populationSARS-CoV-2 reinfections increased substantially after Omicron variants emerged. Large-scale community-based comparisons across multiple Omicron waves of reinfection characteristics, risk factors, and protection afforded by previous infection and vaccination, are limited, especially after widespread national testing stopped. We studied 245,895 adults >=18y in the UK's national COVID-19 Infection Survey with at least one infection (identified from positive swab tests done within the study, linked from national testing programmes, or self-reported by participants, up to their last study assessment). We quantified the risk of reinfection in multiple infection waves, including those driven by BA.1, BA.2, BA.4/5, and most recently BQ.1/CH.1.1/XBB.1.5 variants, in which most reinfections occurred. Reinfections had higher cycle threshold (Ct) values (lower viral load) and lower percentages self-reporting symptoms compared with first infections. Across multiple Omicron waves, protection against reinfection was significantly higher in those previously infected with more recent than earlier variants, even at the same time from previous infection. Protection against Omicron reinfections decreased over time from the most recent infection if this was the previous or penultimate variant (generally within the preceding year), but did not change or even slightly increased over time if this was with an even earlier variant (generally >1 year previously). Those 14-180 days after receiving their most recent vaccination had a lower risk of reinfection with all Omicron variants except BA.2 than those >180 days from their most recent vaccination. Reinfection risk was independently higher in those aged 30-45 years, and with either low or high Ct values in their most recent previous infection. Overall, the risk of Omicron reinfection is high, but with lower severity than first infections; reinfection risk is likely driven as much by viral evolution as waning immunity. ### Competing Interest Statement DWE declares lecture fees from Gilead, outside the submitted work. PCM receives GSK funding to support a PhD fellowship in her team. No other author has a conflict of interest to declare. ### Funding Statement This study is funded by the UK Health Security Agency and the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. Individuals can apply to be an accredited researcher using the short form on https://researchaccreditationservice.ons.gov.uk/ons/ONS_registration.ofml. Accreditation requires completion of a short free course on accessing the SRS. To request access to data in the SRS, researchers must submit a research project application for accreditation in the Research Accreditation Service (RAS). Research project applications are considered by the project team and the Research Accreditation Panel (RAP) established by the UK Statistics Authority at regular meetings. Project application example guidance and an exemplar of a research project application are available. A complete record of accredited researchers and their projects is published on the UK Statistics Authority website to ensure transparency of access to research data. For further information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website.
ExploreLive feeds
About